Glint Pharmaceuticals To Begin Clinical Testing on Contact Lens to Prevent COVID-19 Virus Infection

Share Article

Patented Drug Delivery Technology Incorporates Formulation to Reduce Virus Transmission for the Contact Lens Customer

The patented new lens technology will reduce eye infection caused by Covid-19.

Glint Pharmaceuticals has developed a patented drug delivery contact lens technology for delivery of an anti-COVID 19 formulation to the ocular surface to prevent and treat infection.

The prototype device is in the initial stages of development and Glint expects to conduct safety clinical studies in the coming months. Upon successful completion of the clinical studies the device will be available for consumer use in the 4th quarter of 2020, and will depend on final FDA approval. Recent scientific publications have reported that one route of Covid 19 virus infection is through the eye. “Ocular delivery of an anti-viral and bacterial formulation to the eye surface will have a significant effect in reducing eye infections including Covid-19 transmission”, says Chris Adams, CEO of Glint Pharmaceuticals.

The proprietary formulation combines a well-tolerated ocular chemistry with the Glint drug delivery contact lens to reduce transmission of a broad range of bacteria and viruses including COVID 19. The formulation has been demonstrated to effectively reduce virus load in scientific and medical publications and has been reviewed for effectiveness by the FDA.

The patented drug delivery technology will deliver a measured amount of the anti-infection formulation during the day. Both the contact lens and anti-infection formation have been used extensively on humans without adverse reactions.

About Glint
Glint Pharmaceuticals, a Massachusetts company, is developing proprietary drug delivery technology for the treatment and prevention of ocular infections and diseases. Examples of diseases to be treated include, Covid-19 infection, glaucoma, ocular inflammation, conjunctivitis, allergic rhinitis, and dry eye. Over 40 million Americans suffer from ocular surface disease. The technology has the potential to increase drug efficacy and patient compliance. The Glint Pharmaceuticals anti-Covid-19 lens has not been cleared or approved by the FDA. More information can be found at,

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chris Adams
Visit website